

**Supplementary Materials for: Implementation of a Rapid RT-LAMP Saliva-based SARS-CoV-2  
Testing Program in the Workplace**

Bradley W.M. Cook <sup>1\*</sup>, Kaitlyn Kobasa <sup>1,†</sup>, Marielou Tamayo <sup>1,†</sup>, Natasha Theriault <sup>1,2,†</sup>, Diane Gordon  
Pappas <sup>1</sup>, Steven S. Theriault <sup>1,2</sup>.

**Supplementary Materials**

Table S1: Primer Sets For RT-LAMP Assay and Nucleotide Changes Observed in Variants.

Table S2: GISAID Sequences Used in Study.

## Supplementary Tables:

**Table S1: Primer Sets For RT-LAMP Assay and Nucleotide Changes Observed in Variants.**

Primer Set	Primer Name	Primer Sequence (5'-3')	Alpha	Beta	Gamma	Delta
AS1E	F3	CGGTGGACAAATTGTCAC	NC	NC	NC	NC
	B3	CTTCTCTGGATTTAACACACTT	NC	NC	NC	NC
	Loop F	TTACAAGCTTAAAGAATGTCTGAA CACT	NC	NC	NC	NC
	Loop B	TTGAATTTAGGTGAAACATTTGTCA CG	NC	NC	NC	NC
	FIP	TCAGCACACAAAGCCAAAAATTTA TTTTTCTGTGCAAAGGAAATTAAG GAG	NC	NC	NC	NC
	BIP	TATTGGTGGAGCTAAACTTAAAGC CTTTTCTGTACAATCCCTTTGAGTG	NC	NC	NC	NC
N2	F3	CGGCAGTCAAGCCTCTTC	NC	NC	NC	NC
	B3	TTGCTCTCAAGCTGGTTCAA	NC	NC	NC	NC
	Loop F	This primer was omitted from the set. (Yang et al. 2020)	NA	NA	NA	NA
	Loop B	ATGGCGGTGATGCTGCTCTT	NC	NC	NC	1 (G-->T <sup>*</sup> ) ATGGCTGTGATGCTGCTCTT
	FIP	TCCCCTACTGCTGCCTGGAGCGTTC CTCATCACGTAGTCG	3 (CCC-->GTT <sup>*</sup> ) TCGTTTACTGCTGC CTGGAGCGTTCTT CATCACGTAGTCG	5 (CCC -->GTT <sup>*</sup> , CT-->GA <sup>*</sup> ) TCGTTTAGAGCTGCCTGG AGCGTTCCTCATCACGTA GTCG	1 (C-->A <sup>*</sup> ) TCCCATACTGCTGCCTGGAGCGTT CCTCATCACGTAGTCG	
	BIP	TCTCCTGCTAGAATGGCTGGCATCT GTCAAGCAGCAGCAAAG	NC	NC	NC	NC
ORF1e	F3	GGCTAACTAACATCTTTGGC	1 (C-->T <sup>*</sup> ) GGCTAACTAATAT CTTTGGC	NC	NC	NC
	B3	GTCAGCACACAAAGCCAA	NC	NC	NC	NC
	Loop F	TCTTCAAGCCAATCAAGGAC	NC	NC	NC	NC
	Loop B	TTGTCGGTGGACAAATTGT	NC	NC	NC	NC
	FIP	TCTCTAAGAACTCTACACCTTCCT TTTTACTGTTTATGAAAACTCAAA CC	NC	NC	NC	NC
	BIP	TATCTCAACCTGTGCTTGTAATTT TTAGAATGTCTGAACACTCTCCT	NC	NC	NC	NC
RNase P	F3	TTGATGAGCTGGAGCCA				
	B3	CACCCTCAATGCAGAGTC				
	Loop F	ATGTGGATGGCTGAGTTGTT				
	Loop B	CATGCTGAGTACTGGACCTC				

	FIP	GTGTGACCCTGAAGACTCGGTTTT AGCCACTGACTCGGATC	
--	-----	---	--

\* Change observed in variant

## Supplementary Tables:

**Table S2: GISAID Sequences Used in Study.**

Variant	Isolate	Accession ID	Collection Date	Submission Date
Alpha	hCoV- 19/Canada/MB- NML-16346/2021	EPI_ISL_1594283	2021-01-21	2021-04-15
Beta	hCoV- 19/Canada/MB- NML-17441/2021	EPI_ISL_1594098	2021-01-16	2021-04-15
Gamma	hCoV- 19/Canada/MB- NML-34961/2021	EPI_ISL_1594071	2021-03-31	2021-04-15
Delta	hCoV- 19/Canada/MB- NML-70550/2021	EPI_ISL_2495627	2021-04-29	2021-06-11

All samples were collected from MB-Cadham Laboratory and submitted by the National Microbiology Laboratory (NML) in North America, Canada, Manitoba by: Anna Majer; Anneliese Landgraff; CanCOGeN's metadata curation team; Darian Hole; David Alexander; Elsie Grudeski; Gary Van Domselaar; Grace Seo; Jared Bullard; Jennifer Tanner; Kerry Dust; Kirsten Biggar; Madison Chapel; Morag Graham; Natalie Knox; Nathalie Bastien; Paul Van Caesele; Philip Mabon; Public Health Agency of Canada CanCOGeN team; Rhiannon Huzarewich; Russell Mandes; Shari Tyson; Timothy Booth; Yan Li.